tiprankstipranks
Advertisement
Advertisement

CGEM Stock Latest News

Cullinan Oncology: FDA Acceptance of Zipalertinib NDA and Upcoming CLN-978 Data Underpin Buy Rating and Favorable NPV Outlook
RatingsCullinan Oncology: FDA Acceptance of Zipalertinib NDA and Upcoming CLN-978 Data Underpin Buy Rating and Favorable NPV Outlook
2d ago
CGEM
Cullinan Therapeutics price target raised to $30 from $27 at H.C. Wainwright
PremiumThe Fly
Cullinan Therapeutics price target raised to $30 from $27 at H.C. Wainwright
2d ago
CGEM
Cullinan Therapeutics announces U.S. FDA accepted NDA for zipalertinib
PremiumThe Fly
Cullinan Therapeutics announces U.S. FDA accepted NDA for zipalertinib
3d ago
CGEM
Clear Street says Gilead-Ouro deal highlights upside for Cullinan’s velinotamig
PremiumThe Fly
Clear Street says Gilead-Ouro deal highlights upside for Cullinan’s velinotamig
1M ago
CGEM
GILD
Cullinan Therapeutics price target raised to $36 from $34 at Wedbush
PremiumThe Fly
Cullinan Therapeutics price target raised to $36 from $34 at Wedbush
2M ago
CGEM
Cullinan: Advancing Immunology and Oncology Pipeline Undervalued; Buy Rating on CLN-978 Catalysts and Strong Cash Runway
PremiumRatingsCullinan: Advancing Immunology and Oncology Pipeline Undervalued; Buy Rating on CLN-978 Catalysts and Strong Cash Runway
2M ago
CGEM
Cullinan Management Adopts Reduced SEC Reporting: Lower Compliance Costs, But Potential Hit to Investor Appeal and Liquidity
Premium
Company Announcements
Cullinan Management Adopts Reduced SEC Reporting: Lower Compliance Costs, But Potential Hit to Investor Appeal and Liquidity
2M ago
CGEM
Cullinan Therapeutics reports Q4 EPS (77c), consensus (84c)
Premium
The Fly
Cullinan Therapeutics reports Q4 EPS (77c), consensus (84c)
2M ago
CGEM
Cullinan Therapeutics sees cash runway into 2029
PremiumThe Fly
Cullinan Therapeutics sees cash runway into 2029
2M ago
CGEM
CGEM Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
CGEM Upcoming Earnings Report: What to Expect?
2M ago
CGEM
TheStreet Pro Analysts Say, “It’s a Stock Picker’s Market – Here Are 4 to Consider”
PremiumMarket News
TheStreet Pro Analysts Say, “It’s a Stock Picker’s Market – Here Are 4 to Consider”
2M ago
CL
CAT
Cullinan Therapeutics initiated with a Buy at Citi
PremiumThe Fly
Cullinan Therapeutics initiated with a Buy at Citi
2M ago
CGEM
Cullinan Oncology: Undervalued Autoimmune Pipeline With 2026 CLN-978 Catalysts and Additional Oncology Upside Supporting Buy Rating
PremiumRatingsCullinan Oncology: Undervalued Autoimmune Pipeline With 2026 CLN-978 Catalysts and Additional Oncology Upside Supporting Buy Rating
2M ago
CGEM
TheStreet Pro Analysts Say, “Big Tech Names are Anything But Cheap – Buy These 2 Stocks Instead”
Premium
Market News
TheStreet Pro Analysts Say, “Big Tech Names are Anything But Cheap – Buy These 2 Stocks Instead”
3M ago
KO
KMB
Cullinan Therapeutics initiated with a Buy at Guggenheim
Premium
The Fly
Cullinan Therapeutics initiated with a Buy at Guggenheim
3M ago
CGEM
Cullinan Therapeutics initiated with a Buy at Guggenheim
PremiumThe Fly
Cullinan Therapeutics initiated with a Buy at Guggenheim
3M ago
CGEM
Cullinan: Buy Rating Reiterated on 2026 Clinical Catalysts and Undervalued Pipeline Upside
PremiumRatings
Cullinan: Buy Rating Reiterated on 2026 Clinical Catalysts and Undervalued Pipeline Upside
4M ago
CGEM
Cullinan Therapeutics price target raised to $27 from $26 at H.C. Wainwright
PremiumThe Fly
Cullinan Therapeutics price target raised to $27 from $26 at H.C. Wainwright
4M ago
CGEM
Cullinan Management Outlines Catalyst-Rich 2026 Pipeline Outlook
PremiumCompany Announcements
Cullinan Management Outlines Catalyst-Rich 2026 Pipeline Outlook
4M ago
8K
CGEM
Cullinan Therapeutics price target raised to $30 from $28 at Morgan Stanley
PremiumThe FlyCullinan Therapeutics price target raised to $30 from $28 at Morgan Stanley
4M ago
CGEM
Cullinan Therapeutics provides corporate update, anticipated 2026 milestones
Premium
The Fly
Cullinan Therapeutics provides corporate update, anticipated 2026 milestones
4M ago
CGEM
Cullinan Therapeutics price target raised to $33 from $22 at Clear Street
Premium
The Fly
Cullinan Therapeutics price target raised to $33 from $22 at Clear Street
5M ago
CGEM

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >